Critical tests with oxibendazole against gastrointestinal parasites of ponies.

Twenty ponies were allotted to 4 groups of 5 ponies each, and oxibendazole was orally administered at dose levels of 5, 10, 15, and 20 mg/kg. In the 3 groups of ponies given the largest doses, efficacy against 3 species of Strongylus was between 92 and 100% and that against small strongylids of the genera Cyathostomum, Cylicocyclus, Cylicodontophorus, and Cylicostephanus was more than 99%. All adults and 95 to 100% of larvae of the pinworm Oxyuris equi were removed. In the group of ponies given 5 mg/kg, 86 to 100% of the large strongylids and 84 to 100% of the small strongylids were removed, as were all larval and adult pinworms. Trichostrongylus axei was found only in 4 of the 5 ponies given 5 mg/kg; results were encouraging, but not consistent. Almost all of the Parascaris equorum were found in this group of ponies; no anthelmintic activity was detected at this dose level. Oxibendazole removed approximately 99% of small strongylid 4th-stage larvae. No efficacy against the larval stages of Gasterophilus intestinalis and against Habronema spp and Setaria equina was observed.     

An evaluation of the efficacy of oxfendazole against the common nematode parasites of the horse.

In a controlled trial in naturally-infected young ponies, oxfendazole administered orally at dose-rates of 10 mg per kg and 50 mg per kg resulted in complete elimination of Trichostrongylus axei, Parascaris equorum, Oxyuris equi and adult Strongylus vulgaris. Also, all migrating Strongylus edentatus larvae recovered from the subperitoneal tissues of the flank were found to be dead. Minimum efficiencies of 99.8 per cent and 99.1 per cent were obtained against adult small strongyles (Trichonema spp) and 97.6 per cent and 100 per cent of developing small strongyle larvae at dose-rates of 10 mg per kg and 50 mg per kg respectively. Although the arterial lesions caused by migrating S vulgaris larvae were less severe in the treated compared with the untreated animals, reductions in mean larval numbers over controls were only in the region of 49 to 59 per cent.     

Controlled test and clinical evaluation of dienbendazole against naturally acquired gastrointestinal parasites in ponies

A controlled test was performed to titrate the anthelmintic dosage of dienbendazole in 24 mixed-breed ponies naturally infected with Strongylus vulgaris, S edentatus, and small strongyle species, as determined by parasitic egg and larval counts in feces. Comparison of results of treatment was made among 3 dienbendazole dosages--2.5, 5, and 10 mg/kg of body weight--and a gum (excipient) mixture given by nasogastric intubation. All ponies were euthanatized and necropsied at 7 or 8 days after treatment. Trichostrongylus axei, Habronema muscae, S vulgaris, S edentatus, small strongyles, and Oxyuris equi were efficaciously eliminated in response to all doses of dienbendazole; Gasterophilus spp were not affected by any dose. There were not sufficient numbers of Draschia megastoma, Anoplocephala spp, or Parascaris equorum in the ponies to evaluate drug effect. Changes in the appearance of the intestinal lining were dose-dependent; in the ponies treated with 5 and 10 mg of dienbendazole/kg, the mucosa appeared clean and smooth, though in ponies given 2.5 mg/kg, it appeared clean, but was nodular and moderately reactive to embedded immature small strongyles. In the gum mixture-treated ponies, the large intestinal mucosa was inflamed, with edematous areas, in response to infections caused by large and small strongyles. A limited clinical titration was done in 12 ponies that were fecal culture negative for S vulgaris larvae, although other strongyles were detected. Two ponies in each of 6 groups were given the following dosages: 0 (gum mixture only), 0.5, 1, 2.5, and 5 mg of dienbendazole/kg. One group of 2 ponies was given 5 mg of fenbendazole/kg as a standard treatment control.(ABSTRACT TRUNCATED AT 250 WORDS)     

Oxibendazole: critical anthelmintic trials in equids.

The efficacy of oxibendazole against gastrointestinal parasites of horses was evaluated by the critical test method. Naturally infected ponies of various ages were given single oral doses of 5, 10, or 15 mg-kg of bodyweight. The drug was highly effective against adult large strongylids (Strongylus vulgaris, S edentatus, S equins), adult small strongylids (especially species of the genera Cylicostephanus, Cylicocyclus, Cyaathostomum, and Triodontophorus), and adult and larval stages of the large pinworm, Oxyuris equi. There was no apparent dose-related differences in efficacy. Oxibendazole was less effective against fourth-stage small strongylid larvae than it was against adults. The drug was inactive against stomach bots (Gasterophilus spp), tapeworms (Anoplocephala magna and A perfoliata), lungworms (Dictyocaulus arnfieldi), abdominal worms )Setaria equina), and mature or immature nematodes in locations other than the lumen of the gastrointestinal tract.     

Efficacy of Daily Pyrantel Tartrate (Strongid C) against Strongyles in Ponies on Pasture

A clinical trial was conducted with 2- to 3-year-old ponies to determine the effectiveness against strongyles of 2.64 mg pyrantel tartrate/kg body weight administered in the daily ration throughout a pasture season in Canada. Ten ponies were given the anthelmintic, and 10 were not treated and served as controls. Each group of ponies was on a separate pasture. The mean strongyle eggs/g of feces for each group, before treatment and turnout to pasture, was greater than 2,200. Thereafter, the mean eggs/g feces for the untreated group remained high (1,405−2,294) and those for the treated group decreased markedly to, and remained at, very low levels (0.2−16.8). Strongyle larval counts for the pasture with the untreated ponies rose to 26,790 larvae/kg dry herbage in August, whereas that for the treated group was 610 larvae/kg dry herbage. At the end of the season, two ponies from each group were isolated for 6 weeks and necropsied. The mean number of strongyles in the untreated and treated ponies was 69,288 and 8,452.5, respectively. In the untreated ponies, 21 species of strongyles were found, and approximately 84% of them were from eight species of cyathostomes. In the treated ponies, 14 species of strongyles were found, and approximately 77% were from one species, Cylicostephanus minutus (52.0%), and immature cythostomes (25%). Adverse reactions were not observed in any of the treated ponies. Pyrantel tartrate was highly effective in significantly reducing the strongyle egg and pasture larval counts and the transmission of strongyles during a pasture season.     

Use of oxibendazole for control of cambendazole-resistant small strongyles in a band of ponies: a six-year study

Oxibendazole (OBZ; 10 mg/kg of body weight) was administered to ponies at 8-week intervals to control strongylosis in a breeding band of Shetland-type ponies (n = 29 to 50) from October 1978 through September 1984. A similar use of cambendazole (CBZ; 20 mg/kg of body weight) in this band of ponies during the preceding 4-year period resulted in the survival of a CBZ-resistant population (S) of small strongyles. Effectiveness of OBZ treatments was monitored by pre- and posttreatment counts of the number of strongyle eggs per gram of feces (epg) and of the number of strongyle larvae per gram of feces (lpg). For the first 4 years of the 6-year period, epg and lpg counts were determined for 3 to 5 of the OBZ treatments; during the last 2 years, counts were determined for each treatment. For the 1st year, the mean reduction in epg was 96%. During the 2nd and 3rd years, mean reductions in epg were 80% and 81%, respectively. For the 4th and 5th years, mean reductions in epg were 69% and 43%, respectively. For the 6th year, the mean reduction in epg was 37%. Statistical analyses of the epg data, using the linear plateau method, indicated a significant increase in residual (surviving) strongyle infections after the periodic OBZ treatments, with a mean annual increase in survival of 10.3% for the 6 years. Changes in lpg were variable, but an overall loss of effectiveness of the OBZ treatments was evident. Only infective larvae of small strongyles were observed in the cultures; larvae of 2 species of large strongyles, Strongylus vulgaris and Strongylus edentatus, were conspicuously absent.(ABSTRACT TRUNCATED AT 250 WORDS)     

Critical anthelmintic trials in ponies with oxfendazole and caviphos and concomitant studies on the spontaneous elimination of small strongylids.

The efficacy of the benzimidazole, oxfendazole, and the organophosphate, caviphos, against gastrointestinal parasites of ponies was evaluated by the critcial test method. Oxfendazole (10 mg/kg of body weight) given in single oral doses was 100% effective against adult large strongylids (Strongylus vulgaris, Strongylus edentatus, and Strongylus equinus), 99% effective against adult small strongylids, and 97% effective against 4th-stage small strongylids (genera identified in order of frequency: Cylicostephanus, Cyathostomum, Cylicocyclus, Triodontophorus, Poteriostomum, Oesophagodontus, Cylicodontophorus, Gyalocephalus, and Craterostomum). Caviphos (40 mg/kg of body weight) admixed in the grain ration (horse crunch) was 89% effective against adult large strongylids (S vulgaris and S edentatus) and 99% effective against adult small strongylids (genera identified earlier in order of frequency above), but only 35% effective against 4th-stage small strongylids. Both drugs were effective (100%) against adult and immature pinworms (Oxyuris equi) but ineffective against Habronema spp and Draschia megastoma. Oxfendazole was only 11% effective against stomach bots (Gasterophilus spp); caviphos was 73% effective against these species. During a three-day pretreatment interval, about 34% of the total population of small strongylids was lost spontaneously from the 29 ponies.     

Re-evaluation of ivermectin efficacy against equine gastrointestinal parasites.

Two trials were conducted to confirm the efficacy of ivermectin paste against endoparasites of horses. In these trials, 20 ponies were treated with ivermectin oral paste at 200 mcg x kg body weight once on Day 0, and 20 ponies served as unmedicated controls. The animals carried naturally acquired parasite infections as confirmed by pretrial fecal examination. The animals were necropsied for worm recovery on Days 14, 15 or 16. Parasites recovered were identified to species. Horses treated with ivermectin had significantly (P<0.05) fewer (>99.0% reduction) adult small strongyles (Coronocyclus spp including C. coronatus, C. labiatus, C. labratus; Cyathostomum spp including C. catinatum, C. pateratum; Cylicocyclus spp including C. ashworthi, C. elongatus, C. insigne, C. leptostomum, C. nassatus, C. radiatus; Cylicodontophorus bicoronatus; Cylicostephanus spp including C. asymetricus, C. bidentatus, C. calicatus, C. goldi, C. longibursatus, C. minutus; Gyalocephalus capitatus; Parapoteriostomum spp including P. euproctus, P. mettami; Petrovinema poculatum; Poteriostomum spp including P. imparidentatum, P. ratzii) and adult large strongyles (Strongylus edentatus, S. vulgaris; Triodontophorus spp including T. brevicauda, T. serratus; Craterostomum acuticaudatum) than the controls. Ivermectin was also highly effective (94% to >99%, P<0.05-0.01) against Gasterophilus intestinalis larvae, Habronema spp., Oxyuris equi, Parascaris equorum. The data from these two trials confirm that ivermectin paste administered to horses orally at 200mcg x kg(-1) continues to be highly effective for treatment and control of a broad range of small and large strongyle species as well as other species of gastrointestinal parasites.     

The efficacy of fenbendazole in the control of immature strongyle infections in ponies

The efficacy of fenbendazole against immature stages of Trichonema spp., Strongylus vulgaris and Strongylus edentatus was evaluated. Naturally infected 6 to 12 month old ponies were given single, oral doses of 0, 15, 30 and 60 mg/kg of body weight. A dose response relationship was noted between increasing dose levels and efficiency against larval trichonemes and migrating stages of S. vulgaris and S. edentatus. Dose levels of 30 mg/kg and higher removed 93 per cent of mucosal stages of Trichonema spp., while doses of 60 mg/kg removed 83 per cent and 89 per cent of the migrating larvae of S. vulgaris and S. edentatus respectively.     

Serum protein changes in ponies on different parasite control programmes

Serum protein responses were examined in 52 ponies divided into five groups and subjected to various control strategies that resulted in pasture infectivity ranging from 706 to 18,486 infective third stage, cyathostome and Trichostrongylus axei larvae per kilogram of herbage (L3/kg) by 17 September 1984. Major protein changes occurred only in young ponies (Groups 4 and 5) and were observed before exposure to maximum numbers of pasture larvae (Group 4; 10,210 L3/kg, Group 5: 10,042 L3/kg) on 17 September. It appeared that a primary infection of T axei was a greater stimulus to serum beta-globulin and immunoglobulin (Ig)G(T) responses that provided by continued infection with cyathostome (small strongyle) worms. The large strongyles (Strongylus vulgaris, S edentatus and S equinus) were not detected in any larval cultures or on pastures grazed by the young ponies. A fall in beta-globulin and IgG(T) concentrations of Group 5 ponies one month after treatment with ivermectin indicated a larvicidal action against T axei and/or the cyathostomes. A subsequent rise in serum albumin concentrations of Group 5 ponies suggested that a protein-losing gastroenteropathy had been alleviated by the larvicidal action of ivermectin. Mature control ponies (Group 1) showed little beta-globulin response and only a modest IgG(T) response in six of the 10 ponies after exposure to heavily infected lawns (18,486 L3/kg) in September 1984. It was concluded that serum protein and IgG(T) responses were of limited value as an aid to diagnosis of parasitism because of numerous difficulties of interpretation.     

Efficacy of ivermectin in injectable and oral paste formulations against eight-week-old Strongylus vulgaris larvae in ponies

A controlled test method was used to evaluate the efficacy of injectable micelle and oral paste formulations of ivermectin (22,23-dihydroavermectin B1) against 8-week-old Strongylus vulgaris larvae in experimentally infected pony foals. The dosage level of the drug in both formulations tested was 0.2 mg/kg. Ponies were euthanatized and necropsied 5 weeks after treatment. Based on the recovery of live vs dead S vulgaris from mesenteric arteries, both formulations were greater than 99% effective. Increased weight gains and marked reductions in the severity of arterial lesions were observed in treated ponies.     

Imidocarb and parvaquone in the treatment of piroplasmosis (Babesia equi) in equids

The therapeutic efficacies of imidocarb and parvaquone were tested against Babesia equi of European origin in carrier horses and for induced acute infections in splenectomized ponies. Imidocarb, at a dosage of 4 mg/kg of body weight, given IM at 72-hour intervals 4 times, was ineffective in eliminating B equi-carrier infection in 9 mature geldings. A single IM administration of 4 mg/kg was not therapeutic in acutely infected splenectomized ponies. When given at 3 different dosages and treatment schedules, parvaquone was ineffective in clearing carrier infection. Parvaquone given IM once at a dosage of 20 mg/kg was effective for acute B equi infections in splenectomized ponies; parasitemia began to decrease within 24 hours after treatment. Infections were not eliminated however, and within 4 weeks, secondary parasitemia and anemia developed. Of 4 ponies, 3 died of acute piroplasmosis.     

Evaluations of buparvaquone as a treatment for equine babesiosis (Babesia equi)

We evaluated the efficacy of buparvaquone in eliminating Babesia equi of European origin in carrier horses and in experimentally infected splenectomized ponies. When administered at the rate of 2.5 mg/kg of body weight, IM, 4 times at 96-hour intervals, buparvaquone was effective in eliminating B equi carrier infection in 1 horse. Such results could not be repeated at the same dosage or at 3.5 or 5 mg/kg, IM. Buparvaquone given at the rate of 4 to 6 mg/kg IV and/or IM was therapeutically effective in 4 of 5 acute B equi infections in splenectomized ponies. The treated ponies became carriers.     

Controlled test evaluation of the benzimidazole anthelmintic VET 220-S alone or with concomitant trichlorfon treatment against naturally acquired gastrointestinal parasites in ponies

A controlled test was done in 30 naturally infected ponies to evaluate the antiparasitic activity of the dienbendazole analog VET 220-S given alone or with trichlorfon (TCF) by nasogastric intubation. Six ponies were nontreated; 6 were given VET 220-S (5.0 mg/kg); 6 were given TCF (40 mg/kg); 6 were given VET 220-S (2.5 mg/kg) and TCF (40 mg/kg); and 6 were given VET 220-S (5.0 mg/kg) and TCF (40 mg/kg). All ponies were euthanatized and necropsied 7 or 8 days after treatment. Draschia megastoma, Oxyuris equi, Strongylus vulgaris, S edentatus, and small strongyles were removed efficaciously by all doses of VET 220-S. Habronema muscae and microfilariae of Onchocerca cervicalis were not removed by VET 220-S or TCF. Gasterophilus intestinalis was 97.9% removed by TCF. Pregnant mares in all groups were not adversely affected by treatment, except for 1 mare that had diarrhea after TCF treatment. Parasite eggs per gram and larval culture data agreed with necropsy data.     

Critical test evaluation of butamisole against gastrointestinal parasites of horses and ponies.

A critical test was performed to evaluate the anthelmintic properties of an injectable butamisole formulation and to compare the efficiency with that of a commercially available piperazine-thiabendazole anthelmintic. The test was done in 10 horses and 15 ponies with naturally acquired parasitic infections. Butamisole was administered at the dose level of 2.5 or 3.75 mg/kg of body weight by either subcutaneous or deep intramuscular injection. Given at the dose level of 2.5 mg/kg, butamisole was highly effective (99%) against Strongylus vulgaris and moderately effective (49%) against Parascaris equorum. At the 3.75 mg/kg dose rate, butamisole was highly effective against both S vulgaris (97%) and P equorum (94%). Butamisole had limited efficacy against other parasite species. Signs of toxicosis, long-term swelling of the injection sites, or tissue damage were not seen after injection.     

Strongyle infections in ponies. II. Reinfection of treated animals.

Five of seven ponies whose strongyle worm burdens had previously been removed or markedly reduced by repeated thiabendazole treatments were reinfected with doses ranging from 100,000 to 500,000 small strongyle infective larvae. Reinfection of ponies resulted in the development of clinical signs characterized by abnormal feces, marked loss of weight and delayed shedding of winter hair coats. An abrupt increase in circulating eosinophils occurred during the first three weeks following reinfection. Patent infections developed in all ponies with worm eggs appearing in the feces from 12 to 15 weeks after receiving infective larvae. Worm egg outputs followed a cyclic pattern with approximately four to five peaks in egg output per year. There was an abrupt drop in the high worm egg counts in two untreated ponies approximately two and a half years after reinfection. No worms were recovered in the feces of these animals when they were subsequently treated, suggesting that a depletion in the number of inhibited larvae present in these ponies might have occurred.     

Possible resistance of small strongyles from female ponies in The Netherlands against albendazole

To determine resistance of small strongyles to albendazole, 3 female ponies (group 1) were grazed on a pasture from May to November 1985 and were treated with 7.5 mg of albendazole/kg of body weight, PO, 2 days before turnout in May and again in June and in July. Three other female ponies (group 2) grazed on a similar pasture from May to July, were treated with 7.5 mg of albendazole/kg, and were removed to another pasture until November. In December, ponies from both groups were treated with 7.5 mg of albendazole/kg, and 8 days later, they were euthanatized and necropsied for a critical test. Worm egg counts in the ponies' feces revealed that the May treatment of group 1 and the July treatment of group 2 were more effective than were later treatments. Numbers of small strongyles were higher in group 1 than in group 2. Efficacy of treatment against all developmental stages of small strongyles was higher in group 2 than in group 1. Efficacy was low in both groups against parasitic 3rd- and 4th-stage larvae. Fifteen species of small strongyles were identified at necropsy. Efficacy was limited against adult Cyathostomum coronatum, Cya labratum, Cylicostephanus calicatus, and Cyl poculatus in both groups; Cylicocyclus nassatus, Cyl minutus, and Cyl longibursatus in group 1; and Cya labiatum in group 2. Efficacy was 100% against Cya catinatum, Cyl goldi, and 5 other species that were found in low numbers.     

Efficacy of avermectin B1 given orally against equine intestinal strongyles and Onchocera microfilaria

Three groups of horses and ponies (N = 13, 13 and 12) were treated with ivermectin paste (0.2 mg/kg p.o.), avermectin B1 solution (0.2 mg/kg p.o.), or fenbendazole suspension (10 mg/kg via nasogastric tube). The avermectin B1 was a 1% solution in a propylene glycolglycerol formal base. Faecal strongyle egg counts were performed before, and 14, 28, 42, 56 and 70 d, after treatment. Full-thickness skin biopsies from the neck, pectoral and umbilical regions were examined for Onchocera microfilaria before treatment, and again 14 and 70 d later. Ivermectin therapy produced a significant (P less than 0.01) decrease in mean strongyle egg counts 14, 28, 42 and 56 d after treatment. Avermectin B1 therapy resulted in significant (P less than 0.01) decreases in mean strongyle egg counts 14, 28 and 42 d after treatment. All horses given ivermectin or avermectin B1 had zero strongyle egg counts 14 and 28 d after treatment. Fenbendazole failed to significantly decrease strongyle egg counts. Both ivermectin and avermectin B1 resulted in zero microfilaria counts in all horses 14 d after treatment. On day 70 the percentage decrease in microfilaria counts were 100% and 99.6% respectively. Fenbendazole failed to significantly decrease microfilaria counts. The oral administration of this formulation of avermectin B1 appeared to be highly efficacious against intestinal strongyles and Onchocera microfilaria. The duration of anti-strongyle activity was, however, significantly (P less than 0.01) shorter than that of ivermectin paste.     

Evaluation of ivermectin paste in the treatment of ponies for Parascaris equorum infections

Twenty ponies less than 18 months of age and infected with Parascaris equorum were treated with either 0.2 mg of ivermectin/kg of body weight (n = 10) or a placebo (n = 10; controls). Five control and 5 ivermectin-treated ponies were euthanatized 14 and 35 days after treatment, respectively. At necropsy, the small intestinal contents, lungs, and liver were examined for larvae and/or adult P equorum. Significantly (P less than 0.02) higher mean total numbers of P equorum were found in the small intestinal contents of the controls on day 14 (51) and on day 35 (21) than in the ivermectin-treated ponies on days 14 (0) and 35 (3). The efficacy of ivermectin in removing adult and intestinal larvae of P equorum at 14 days after treatment was 100%. The efficacies of ivermectin in removing adults and intestinal larvae of P equorum at 35 days after treatment were 100% and 76.9%, respectively. Gross examination of liver and lung tissues revealed damage as a result of P equorum infections in all ponies. The Baermann technique used on liver and lung tissues did not yield any P equorum larvae. Adverse reactions attributable to treatment were not observed.     

Clinical efficacy of prophylactic administration of trimethoprim/sulfadiazine in a Streptococcus equi subsp. zooepidemicus infection model in ponies

Tissue chambers, implanted subcutaneously in the neck in six ponies, were inoculated with Streptococcus equi subsp. zooepidemicus in order to determine the clinical efficacy of prophylactic administration of trimethoprim/sulfadiazine (TMP/SDZ) against this infection. The TMP/SDZ treatment consisted of one intravenous (i.v.) injection of 5 mg/kg TMP and 25 mg/kg SDZ and the same dose of TMP/SDZ per os (p.o.), both given 3 h before inoculation. The oral dose was then repeated every 12 h for 5 days. TMP/SDZ concentrations in tissue chamber fluid (TCF) were above 10 times MIC at the moment of inoculation, and they were maintained at this level or higher throughout the duration of treatment. Trimethoprim/sulfadiazine treatment resulted in a marked reduction of viable bacteria in the tissue chamber but did not eliminate the infection, resulting in abscessation from day 19 onwards in all six ponies. This shows that, even when TCF is not yet purulent, TMP/SDZ is unable to eliminate the streptococci. Therefore, TMP/SDZ should not be the antimicrobial treatment of choice in infections in secluded sites in horses.